Activating mutations of epidermal growth factor receptor (EGFR) are identified in about 20% of lung adenocarcinomas in Western countries [6] and 40%–60% of lung adenocarcinomas in East Asia [7–9]. The gene discussed is EGFR; the disease is lung adenocarcinoma.